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This teaching lecture will focus on esophageal and gastric cancer. It 
remains a challenge to treat these patients outside a context of 
clinical trials. 
Different published delineation guidelines will be discussed and 
compared in esophageal and gastric cancer. The role of imaging 
modalities such as endoscopy, endoscopic ultrasound, CT scan, FDG-
PET-CT in the delineation process and during (chemo) radiotherapy 
will be highlighted. 
Whether squamous cell carcinoma and adenocarcinoma of the 
esophagus can be regarded as one tumor entity remains unclear. The 
same holds true for adenocarcinomas of the GE junction and the 
stomach.  
Organs at risk and dose constraints will be considered. The challenge 
of organ motion and tumor shrinkage during a course of (preoperative) 
chemoradiation will be discussed. 
Learning objectives: 
1. To understand the impact on target definition and delineation when 
comparing preoperative versus postoperative chemoradiation 
2. To understand the impact of different imaging modalities on the 
delineation process 
3. To understand the impact of organ motion during treatment 
4. To understand the impact of tumor shrinkage  during treatment 
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As part of a comprehensive approach to quality assurance in the 
treatment of cancer by radiation, an independent external audit (peer 
review) is important to ensure adequate quality of practice and 
delivery of treatment [1]. Historically, clinical audits in radiotherapy 
have been promoted by IAEA, after the development of a specific 
methodology in which ESTRO members played an active role. It is 
available on the IAEA website under the name QUATRO (quality 
assurance team for radiation oncology). 
To capture the actual level of competence of a department, the audit 
addresses simultaneously the issues of equipment, infrastructure and 
operation of clinical practice. A major part of the audit is patient 
oriented. It is carried out by experts inthe 3 main disciplines: RTT, 
medical physics and radiation oncology. 
A clinical audit is not a pass or fail test; it is a process by which a 
comprehensive quality management system is measured against pre-
defined standards or codes of good practice. Its result is a series of 
recommendations that could fall in 3 categories: (1) urgent corrective 
actions needed (with or without consecutive re-audit), (2) corrective 
actions to be implemented in the future without urgent need, and (3) 
no specific recommendations. The latter category implies that the 
department runs at an appropriate level of qualityand safety. This 
does not mean that quality and safety have been achieved, as both 
should be permanently developed and updated, but that the 
department has adynamic and organised management system that 
constantly checks upon their appropriateness.  
An appropriate management system is a system with an organized 
prospective and retrospective quality and safety monitoring, a system 
that learns from its mistakes (implying that mistakes are actively 
recorded and analysed), and a system reactive to innovation 
(proactive safety management through FMEA). Indeed, quality is not a 
goal, quality is away. 
Well over 50 hospitals have been already audited in Europe (Central 
and Eastern) and, in some countries, the clinical audits are already a 
legal requirement, in compliance with EURATOM directives. 
Morerecently, Belgium, through its Federal College of Radiotherapy, 
has started a program for systematic auditing of radiotherapy 
departments, drawing upon the IAEA experience and with the help of 
some of its experts. Ten hospitals have already been audited (out of 
25) and results will be presented at theconference. 
[1]Comprehensive Audits of Radiotherapy Practice: a tool for Quality 
Improvement.IAEA, Vienna, 2007 (http://www.iaea.org/books). 
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The tumor microenvironment contributes to cancer invasion, growth 
and survival and thereby impacts tumor responses to therapy. We here 
developed an intravital infrared multiphoton imaging model for the 
multi-parameter visualization of collective cancer cell invasion, 
guidance by the tumor stroma, and short- and long-term resistance to 
experimental anti-cancer therapy. The data show for orthotopic 
fibrosarcoma and melanoma xenografts deep invasive growth driven 
by proliferation concurrent with collective invasion of multicellular 
strands along the normoxic perivascular stroma. Invasion was fast (up 
to 200 µm per day), non-destructive and independent of β1 and β3 
integrins. Despite normoxia, perivascular invasion strands were 
resistant to high-dose hypofractionated irradiation which otherwise 
was sufficient to induce regression of the tumor main mass. This 
invasion-associated radioresistance was sensitive to the simultaneous 
inhibition of β1 and β3 integrins by RNA interference or combined 
anti-β1/aV integrin antibody treatment caused by proliferation arrest, 
anoikis induction ablating both tumor lesion and invasion strands. In 
conclusion, collective invasion is an important invasion mode in solid 
tumors into a microenvironmentally priviledged survival niche which 
conveys radioresistance by integrin-dependent signals. These findings 
show how “dynamic in vivo cell biology” identifies a key role for 
integrin-mediated signaling in mediating cross-talk (reciprocity) 
between the peri-tumor stroma and the tumor cells to mediate 
altered biology and response to therapy (plasticity). 
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This paper presents the main elements of the new Radiation 
Protection and Safety of Radiation Sources: International Basic Safety 
Standards (the BSS) as it relates to the field of medical radiation 
physics and highlights the potential benefits for the professionals 
working in this field.  
The BSS is developed by the IAEA and the co-sponsoring organizations 
through an open and transparent process including inputs from IAEA 
Member States and international organizations such as the 
International Organization for Medical Physics (IOMP). The BSS 
contains a chapter giving the general requirements covering all 
practices, including uses of radiation in medicine, research and 
teaching, and also emergency exposure situations and existing 
exposure situations. This is followed by three chapters giving detailed 
requirements for each of the three exposure situations, one of which 
addresses medical exposure. The section on medical exposure covers 
the responsibilities of those involved including medical physicists, the 
justification of medical exposures, the optimization of protection 
covering design and operational considerations, calibration, dosimetry 
of patients, diagnostic reference levels and quality assurance, the 
release of patients after radionuclide therapy, the investigation of 
unintended and accidental medical exposure, and records. The BSS 
plays an important role in many countries; it is often taken as a 
template for national regulations, and it is mandatory for those 
countries receiving technical cooperation assistance from the IAEA.  
In the field of medical radiation physics, significant changes have 
been introduced in the new BSS. First, the medical physicist is 
identified in the new BSS as one of the key professionals, together 
with the radiological medical practitioner and technologist/ 
radiographer, with responsibilities for quality assurance and patient 
radiation protection. Training and clinical competence requirements 
for medical physics practice are identified in the BSS. Medical 
physicists can practice only if they are specialized in the appropriate 
area, such as radiotherapy,nuclear medicine, diagnostic radiology or 
image guided interventional procedures. The details of the 
specialization have to be defined at the national level by the relevant 
professional body, health authority or other appropriate organization. 
According to the BSS, for therapeutic uses of radiation, the 
requirements for calibration, dosimetry and QA, including the 
acceptance and commissioning of medical radiological equipment, 
need to be fulfilled by or under the supervision of a medical physicist. 
For diagnostic uses and image-guided interventional procedures, the 
requirements for imaging, calibration, dosimetry and QA, including 
